Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Novavax
NVAX
Novavax
Heightened Regulation And A Narrow Portfolio Will Shrink Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
22 Aug 25
Updated
22 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$6.00
30.7% overvalued
intrinsic discount
22 Aug
US$7.84
Loading
1Y
-34.6%
7D
-18.2%
Author's Valuation
US$6.0
30.7% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$6.0
30.7% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-1b
2b
2014
2017
2020
2023
2025
2026
2028
Revenue US$107.2m
Earnings US$17.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-31.41%
Biotech revenue growth rate
11.77%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.91%
Calculation
US$17.42m
Earnings '28
x
71.12x
PE Ratio '28
=
US$1.24b
Market Cap '28
US$1.24b
Market Cap '28
/
169.32m
No. shares '28
=
US$7.32
Share Price '28
US$7.32
Share Price '28
Discounted to 2025 @ 6.91% p.a.
=
US$5.99
Fair Value '25
